Applications of (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-Methoxyphenyl)Diphenylmethyl]Amino]-6-(Phenylmethoxy)-9H-Purin-9-Yl]-2-(Benzyloxymethyl)Cyclopentanol in Industrial Manufacturing

As a manufacturer specializing in advanced chemical intermediates, we facilitate high-value downstream production with (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-Methoxyphenyl)Diphenylmethyl]Amino]-6-(Phenylmethoxy)-9H-Purin-9-Yl]-2-(Benzyloxymethyl)Cyclopentanol, which plays a crucial role in purine nucleoside analog synthesis, pharmaceutical API development, advanced biochemical research reagents, and diagnostic compound production. The applications described below reflect industry-adopted processes and established usage standards across key sectors.

1. Nucleoside Analog Antiviral API Synthesis

Pharmaceutical manufacturers use this compound as a protected sugar intermediate in the synthesis of complex nucleoside analog active pharmaceutical ingredients (APIs), especially where amino-protected cyclopentanol motifs are required. Its precise configuration and protecting group stability supports reliable multistep synthesis of antivirals like entecavir and related molecules. Strict adherence to GMP and pharmacopeial requirements is essential throughout production, as these APIs are destined for direct human therapeutic use.

Industry compliance standards

• International Council for Harmonisation (ICH Q7) Good Manufacturing Practice for APIs
• USP-NF/EP/JP monographs for nucleoside APIs
• 21 CFR Part 211 (FDA cGMP for finished pharmaceuticals)
• EU EudraLex Volume 4 (GMP guidelines)

Typical usage ratio

• 0.9–1.2 molar equivalents as a key glycosylation building block, adjusted based on target yield and desired purity, typically at a 1:1 ratio with the purine base during coupling.

Downstream process integration

• Enters the synthesis train after the functionalization of purine bases, followed by nucleophilic substitution and subsequent deprotection steps prior to final API crystallization.

Final product types

• Oral solid dose antivirals (e.g., tablets, capsules)
• Injectable formulations of nucleoside analog APIs
• Reference standards for pharmaceutical quality control labs
• Bulk API intermediates for contract manufacturing organizations (CMOs)

2. Oncology Research Compound Synthesis

This intermediate supports oncology drug discovery, providing the structural backbone for high-purity, chiral nucleoside analogs under investigation as antimetabolite agents. Medicinal chemists use it in controlled pilot scale synthesis for SAR (structure-activity relationship) studies and to generate libraries of novel purine-based candidates for preclinical screening. Analytical traceability and batch purity remain critical due to downstream pharmacological assays.

Industry compliance standards

• OECD Good Laboratory Practice (GLP) for non-clinical safety studies
• ICH Q14/Q6B for analytical procedures and specifications
• Global harmonized system (GHS) labeling and handling
• REACH/CLP regulations (where applicable for research chemicals)

Typical usage ratio

• 0.5–1.0 mmol per synthesis batch, with ratio determined by screening scale and target compound diversity; higher usage in focused analog libraries.

Downstream process integration

• Used after initial purine core assembly as a chiral synthon, typically in glycosylation reactions under anhydrous or phase-transfer conditions, before purification and subsequent biological evaluation.

Final product types

• Preclinical oncology drug candidates for in vitro and in vivo testing
• Reference materials for medicinal chemistry teams
• Custom nucleoside analog collections for pharmacokinetic profiling
• Building blocks for further structural modification

3. Diagnostic Oligonucleotide Synthesis

In the diagnostics sector, (2R,3S,5S)-cyclopentanol derivatives allow for the preparation of modified oligonucleotide probes and primers with enhanced binding specificity or enzyme resistance, integral to real-time PCR, DNA sequencing, and hybridization assays. Integration into solid-phase oligonucleotide synthesis workflows ensures batch consistency and traceable modification incorporation, supporting both clinical diagnostics and research assay kit manufacture.

Industry compliance standards

• ISO 13485:2016 for in vitro diagnostics (IVD) manufacturing
• US FDA 21 CFR 820 Quality System Regulation for medical devices
• Clinical and Laboratory Standards Institute (CLSI) guidelines
• IVDR (EU 2017/746) for diagnostics products in Europe

Typical usage ratio

• 0.01–0.05 mmol per oligonucleotide assembly, based on synthesis throughput and length, optimized to match coupling efficiency and probe design.

Downstream process integration

• Introduced as a protected sugar module during phosphoramidite synthesis steps on automated DNA/RNA synthesizers, prior to cleavage and deprotection.

Final product types

• Synthetic DNA/RNA probes with modified backbones
• PCR and qPCR diagnostic kits
• Sequencing library preparation reagents
• Labeled oligonucleotide molecular diagnostics kits

4. Biochemical Assay Standard Production

Specialty chemical suppliers manufacture assay standards containing this purine analog for calibration of chromatographic, mass spectrometric, and enzymatic detection systems. Consistent structural fidelity and lot traceability are essential, as these standards underpin commercial kit accuracy for pharmaceutical QC and life science R&D labs. The material’s purity directly impacts quantification limits and assay sensitivity, driving stringent quality assurance processes during manufacturing.

Industry compliance standards

• ISO 17034:2016 for reference material producers
• ISO/IEC 17025 for chemical and biological testing laboratories
• ICH Q3A/B for impurity profiles in standards
• USP General Chapter <11> “Reference Standards”

Typical usage ratio

• 5–50 mg per calibration batch, selected based on instrument sensitivity range and standard solution preparation protocols.

Downstream process integration

• Added as a solid or in solution during formulation of analytical standard blends, followed by lyophilization and sealed packaging for shipment to QC and R&D laboratories.

Final product types

• Quantitative nucleoside analog assay standards
• Calibration materials for LC/MS and HPLC
• Certified reference materials for pharmaceutical validation
• Biochemical assay kit calibration solutions